These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27881095)

  • 21. Cognitive impairment in multiple sclerosis.
    Jongen PJ; Ter Horst AT; Brands AM
    Minerva Med; 2012 Apr; 103(2):73-96. PubMed ID: 22513513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.
    Jacobsen C; Hagemeier J; Myhr KM; Nyland H; Lode K; Bergsland N; Ramasamy DP; Dalaker TO; Larsen JP; Farbu E; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1109-15. PubMed ID: 24554101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalamic atrophy and cognition in multiple sclerosis.
    Houtchens MK; Benedict RH; Killiany R; Sharma J; Jaisani Z; Singh B; Weinstock-Guttman B; Guttmann CR; Bakshi R
    Neurology; 2007 Sep; 69(12):1213-23. PubMed ID: 17875909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cognitive impairment in multiple sclerosis].
    Karlińska I; Selmaj K
    Neurol Neurochir Pol; 2005; 39(2):125-33. PubMed ID: 15871058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between cognitive and clinical disability across MS subtypes: The role of the underlying brain damage.
    Gois LCP; Pimentel-Silva LR; Damasceno BP; Damasceno A
    Mult Scler Relat Disord; 2021 Feb; 48():102701. PubMed ID: 33477004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
    Guevara C; Garrido C; Martinez M; Farias GA; Orellana P; Soruco W; Alarcón P; Diaz V; Silva C; Kempton MJ; Barker G; de Grazia J
    Front Neurol; 2019; 10():788. PubMed ID: 31396148
    [No Abstract]   [Full Text] [Related]  

  • 27. The contribution of MRI in assessing cognitive impairment in multiple sclerosis.
    Filippi M; Rocca MA; Benedict RH; DeLuca J; Geurts JJ; Rombouts SA; Ron M; Comi G
    Neurology; 2010 Dec; 75(23):2121-8. PubMed ID: 21135387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.
    Opfer R; Krüger J; Spies L; Hamann M; Wicki CA; Kitzler HH; Gocke C; Silva D; Schippling S
    Neuroimage Clin; 2020; 28():102478. PubMed ID: 33269702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis.
    Radü EW; Bendfeldt K; Mueller-Lenke N; Magon S; Sprenger T
    Swiss Med Wkly; 2013; 143():w13887. PubMed ID: 24264439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
    Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
    J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis.
    Benedict RH; Carone DA; Bakshi R
    J Neuroimaging; 2004 Jul; 14(3 Suppl):36S-45S. PubMed ID: 15228758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain atrophy assessment in multiple sclerosis: importance and limitations.
    Giorgio A; Battaglini M; Smith SM; De Stefano N
    Neuroimaging Clin N Am; 2008 Nov; 18(4):675-86, xi. PubMed ID: 19068408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting clinical progression in multiple sclerosis after 6 and 12 years.
    Dekker I; Eijlers AJC; Popescu V; Balk LJ; Vrenken H; Wattjes MP; Uitdehaag BMJ; Killestein J; Geurts JJG; Barkhof F; Schoonheim MM
    Eur J Neurol; 2019 Jun; 26(6):893-902. PubMed ID: 30629788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects.
    Sastre-Garriga J; Pareto D; Rovira À
    Neuroimaging Clin N Am; 2017 May; 27(2):289-300. PubMed ID: 28391787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
    Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
    Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.
    Bagert B; Camplair P; Bourdette D
    CNS Drugs; 2002; 16(7):445-55. PubMed ID: 12056920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-dimensional measurements with cut-off values are useful for assessing brain volume, physical disability, and processing speed in multiple sclerosis.
    Nishizawa K; Fujimori J; Nakashima I
    Mult Scler Relat Disord; 2022 Mar; 59():103543. PubMed ID: 35078126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
    Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings.
    Piras MR; Magnano I; Canu ED; Paulus KS; Satta WM; Soddu A; Conti M; Achene A; Solinas G; Aiello I
    J Neurol Neurosurg Psychiatry; 2003 Jul; 74(7):878-85. PubMed ID: 12810771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.